The importance of bone marrow reserve is an issue also in lymphoproliferative diseases, where the use of TPO-RA induces an overall response of about 40–50% (58), which increases to 70–80% (the same of primary ITP), if considering only true immune-mediated thrombocytopenia. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.